MHRA Drug Safety Update: Semaglutide (Wegovy®, Ozempic® and Rybelsus®): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management and cardiovascular risk reduction. Patients reporting a sudden loss of vision (including partial loss) while [...]
The post MHRA Drug Safety Update: Semaglutide (Wegovy®, Ozempic® and Rybelsus®): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) appeared first on Community Pharmacy England.
Recent Comments